Herrero et al. have recently demonstrated the utility of ExoGAG technology to enrich for EVs in patients with endometrial cancer, and to facilitate detection of two known prognostic and predictive endometrial cancer biomarkers; L1 cell adhesion molecule (L1CAM) and Annexin A2 (ANXA2) in the samples (155). This evidence concerns the gene L1CAM and endometrial cancer.